The U.S. Food and Drug Administration regulates medical products with nano-scale components and therefore is required to address the safety and biological effects of nanomaterials or materials with nano-scale features used in these products. The Center for Devices and Radiological Health/FDA is conducting studies of various nanomaterials and evaluating the utility of existing material characterization techniques and in vitro and in vivo toxicology assays. This seminar will summarize recent research activities at CDRH/FDA and highlight issues encountered in the characterization and biological responses of some prototypic nanomaterials.
Researchers should cite this work as follows:
CIVIL 1252, Purdue University, West Lafayette, IN